VPTDF - Ventripoint Expands United Kingdom Marketing with New Distribution Partner CardioLogic
(TheNewswire)
Toronto, Ontario – TheNewswire –December 21, 2021 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce a distributor partnershipwith CardioLogic Ltd. ( www.cardiologic.co.uk ) .
“After interviewing a number of potentialdistribution partners in the United Kingdom (UK), we are pleased tohave come to an agreement with CardioLogic. CardioLogic’s positionas a leader in the cardiology market in the UK and its extensivenetwork provides an excellent opportunity for Ventripoint to reach newcustomers in the UK market quickly,” stated Dr. George Adams, CEO ofVentripoint.
Martyn Dixon, Managing Director of CardioLogic,commented: “We are very excited to enter into this partnership withVentripoint Diagnostics and integrate the VMS+ with our range ofinnovative products that we currently offer. In addition to being agreat and a unique complement for cardiac ultrasound, they havedemonstrated an accuracy equivalent to cardiac MRI. We are eager tocommence this partnership and look forward to leveraging the VMS+3.0with our extensive network of client contacts to drive adoption andgrowth into the UK market.”
CardioLogic Ltd specializes in the development,marketing, and distribution of medical devices for cardiac care andhas an extensive network and customer base. Ventripoint does haveprominent UK hospitals using the VMS+3.0, but the UK market is largelyuntapped. CardioLogic will expand Ventripoint’s UK footprint with asales team calling on echocardiologists, interventional cardiologistsand cardiac surgeons, who would benefit from the VMS+3.0 system’sfast and reliable diagnostic imaging. The process for purchase orlease of medical devices in the UK is controlled by Health Trusts andthe National Health Service (NHS) and CardioLogic’s experience indealing with these processes will accelerate the approval of sales andallow a more rapid expansion into hospitals and cardiac facilitiesacross the UK.
The Company continues to interview regionaldistributors for Europe and the United States and expects to haveadditional partnerships to announce in the near future.
Heart Disease in the UK
According to the British Heart Foundation ( https://www.bhf.org.uk ),heart:
-
Circulatory diseases cause a quarter of all deaths inthe UK, that’s more than 160,000 deaths each year – an average of460 deaths each day or one every three minutes in the UK.
-
There are around 7.6 million people living with a heartor circulatory disease in the UK: 4 million men and 3.6 million women.
-
There are more than 100,000 hospital admissions eachyear due to heart attacks: that's one every five minutes.
-
More than 900,000 people in the UK are living withheart failure.
-
The NHS identifies cardiovascular diseaseas a clinical priority and the singlebiggest condition where lives can be saved by the NHS over the next 10years ( https://www.longtermplan.nhs.uk/online-version/chapter-3-further-progress-on- care-quality-and-outcomes/better-care-for-major-health-conditions/cardiovascular-disease/ ).
About CardioLogic Ltd. ( www.cardiologic.co.uk )
CardioLogic works with novel technologies to improveboth the treatment and the standard of care for cardiology, cardiacsurgery and stroke patients. CardioLogicpartners with leading-edge cardiac medtech companies to providesupport through development, marketing, and distribution of innovativemedical devices and products. CardioLogic uses a dedicated sales teamto work with cardiologists, cardiac surgeons to connect cardiacprofessionals to technology that will improve the treatment andstandard of care for cardiac patients throughout the UK.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
About VMS+ Technology
VMS+ (Ventripoint Medical System Plus) 3.0 marries thehigh-resolution of cardiac MRI (Magnetic Resonance Imaging) and easeof use of ultrasound with the power of Ventripoint’s proprietary KBR(Knowledge-Based Reconstruction) AI technology. KBR enables physiciansto construct a precise 3D model of the heart and calculate volumes andejection fractions for all chambers of the heart with an accuracyequivalent to MRI using standard ultrasound images obtained using anycardiac ultrasound machine such as General Electric, Phillips,Siemens, etc.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are based on certain key expectations andassumptions made by the Company. Although the Company believes thatthe expectations and assumptions on which such forward-lookingstatements and information are based are reasonable, undue relianceshould not be placed on the forward-looking statements and informationbecause the Company can give no assurance that they will prove to becorrect.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2021 TheNewswire - All rights reserved.